Kumar, Ashok and Danny, Geo and Renuka, Sane Roja and Salam, Arisha (2021) Lights and Shadows of Rituximab in Dermatology. Journal of Pharmaceutical Research International, 33 (60B). pp. 179-187. ISSN 2456-9119
![[thumbnail of 6579-Article Text-8998-1-10-20221006.pdf]](http://article.stmacademicwriting.com/style/images/fileicons/text.png)
Text
6579-Article Text-8998-1-10-20221006.pdf - Published Version
Download (420kB)
Abstract
Rituximab is a CD 20 monoclonal antibody drug used in various spectrum of diseases today. It has proven to be a boon, especially in the field of dermatology. Although Rituximab was initially introduced as a novel method to treat B-cell Non Hodgkin Lymphoma, its use has rapidly expanded to include a number of other Lymphomas and Autoimmune diseases.This review is to give a bird’s eye view of updates on rituximab.
Conclusion: With its horizons expanding in dermatology, and with better information regarding its efficacy and safety profile, Rituximab has now become an approved first‑line therapy for pemphigus. In conclusion, Rituximab has proven to be a substantial boon for dermatologists in difficult to treat cases.
| Item Type: | Article |
|---|---|
| Subjects: | West Bengal Archive > Medical Science |
| Depositing User: | Unnamed user with email support@westbengalarchive.com |
| Date Deposited: | 29 Mar 2023 06:50 |
| Last Modified: | 29 Jun 2024 12:25 |
| URI: | http://article.stmacademicwriting.com/id/eprint/126 |
Actions (login required)
- View Item